

Prevalence of hypothyroidism in ischemic heart disease

Raghavendra L¹, Shivakumar KM², Anikethana GV³¹Department of Medicine, Mandya Institute of Medical Sciences, Mandya, Karnataka, India²Department of Medicine, Mandya Institute of Medical Sciences, Mandya, Karnataka, India³Department of Medicine, Mandya Institute of Medical Sciences, Mandya, Karnataka, India

Original Research Article

*Corresponding author

Dr Raghavendra L

Article History

Received: 30.09.2017

Accepted: 06.10.2017

Published: 30.10.2017



Abstract: Cardiovascular diseases affect younger population in developing countries like India and carry a higher mortality rate. Common risk factors responsible for myocardial infarction in India are dyslipidemia, smoking, hypertension, diabetes, abdominal obesity, physical inactivity, low fruits and vegetables intake, and psychosocial stress. Other risk factors account for lesser number of cases, one such risk factor being hypothyroidism. A retrospective study was done using hospital records who were admitted with the diagnosis of acute coronary syndrome during the period January 2014 to June 2017. A total number of 326 patients were admitted with acute coronary syndrome, out of these patients 93 (28.53%) were screened with thyroid profile (male 30, female 63). Female patients were more likely to be screened with thyroid profile than male patients (p value <0.0001). 17.2% (16) of the patients had thyroid abnormality. Three female patients had subclinical hypothyroidism. Four male and nine female patients had 'low T3 syndrome'. Of the 93 patients there were 7 deaths (7.5%). In the low T3 group the mortality was 38.5%. The mortality in the low T3 group was significantly higher and statistically significant (p value 0.0062), compared to euthyroid subjects. The study highlights the fact that low T3 syndrome in patients with acute coronary syndrome (NSTEMI and STEMI) acts as a poor prognosis factor. The study also highlights the fact that, screening is less commonly utilised in patients with acute coronary syndrome.

Keywords: hypothyroidism, acute coronary syndrome, atherosclerosis, thyroid profile, subclinical hypothyroidism, low T3 syndrome.

INTRODUCTION

Cardiovascular diseases affect younger population in developing countries like India and carry a higher mortality rate [1]. Coronary artery disease were responsible for 32% of adult deaths in India between 2010-13, according to The Registrar General of India [2]. The age adjusted CVD mortality in India, as per WHO data, is 349/100,000 in men and 265/100,000 in women. These rates are 2-3 times greater than in the United States [3]. The INTERHEART study [4], established 8 common risk factors responsible for 90% of myocardial infarction in India. These are dyslipidemia, smoking, hypertension, diabetes, abdominal obesity, physical inactivity, low fruits and vegetables intake, and psychosocial stress. Other risk factors account for lesser number of cases, one such risk factor being hypothyroidism.

Rotterdam study [5], found that subclinical hypothyroidism was associated with atherosclerosis and with an increased incidence of myocardial infarction in aging female population. Subclinical hypothyroidism

was associated with lipid abnormalities [6], atherosclerotic plaque progression [7] hypertension [8], and endothelial dysfunction [9]. Subclinical hypothyroidism was associated with increased mean platelet volume (MPV), which is a risk factor for infarction [10]. Patients with hypothyroidism have significantly increased level of homocysteine, vWf level and dyslipidemia [11]. Thyroid hormones critically regulate cardiac function through several genes encoding important structural and functional proteins in the myocardium [12].

Increased levels of TSH was associated with higher thrombus burden irrespective of other risk factors, in patients with NSTEMI [13]. Subclinical hypothyroidism was associated with increased risk of cardiovascular disease and cardiovascular disease related mortality [14, 15].

Correction of hypothyroidism with thyroxine supplementation was associated with improved endothelial function [16] reduced progression of

angiographic coronary artery disease [17], improve atherogenic lipid profile [18], and have positive effect on cardiac function [19,20]. Patients with adequate thyroid supplementation had lower major adverse cardiovascular events [21].

The low T3 syndrome, also called nonthyroidal illness syndrome or euthyroid sick syndrome, is defined by a drop in the serum free T3 levels, with normal serum free T4 and TSH levels, with increased reverse free T3 level [22]. Low T3 syndrome may be related to altered systemic homeostasis caused by acute ischaemic event [23] or inflammatory cytokines [24, 25], or both. Low T3 syndrome is related to increased early and late mortality in NSTEMI [26].

METHODS

Hospital records were retrospectively studied from the period of January 2014 to June 2017. Patients admitted with diagnosis of acute coronary syndrome during this period were included in the study. The case records were utilised to obtain the thyroid profile, whenever done. The final outcome of the patient was also recorded.

Patients with renal failure, chronic obstructive airway disease, liver cirrhosis, active infection,

uncontrolled diabetes mellitus and / or using corticosteroids or amiodarone were excluded from the study.

RESULTS

A total of 326 patients were admitted during this period with a diagnosis of acute coronary syndrome (male 229 and female 97). Out of these patients 93 (28.53%) were screened with thyroid profile (male 30, female 63). Female patients were more likely to be screened with thyroid profile than male patients (p value <0.0001). 17.2% (16) of the patients had thyroid abnormality. Three female patients had subclinical hypothyroidism. Four male and nine female patients had ‘low T3 syndrome’.

Low T3 syndrome was more common as the age of the patients increased. The average age of patient with euthyroid status was 55.1 years as against average age of 62.7 Years in low T3 syndrome.

Of the 93 patients there were 7 deaths (7.5%). In the low T3 group the mortality was 38.5%. The mortality in the low T3 group was significantly higher and statistically significant (p value 0.0062), compared to euthyroid subjects.

Table-1: Characteristics of the study subjects

	Euthyroid patients	Low T3 syndrome	Subclinical hypothyroidism
Age	55.1 ± 10.3 years	62.7 ± 5.2 years	58.4 ± 7.3 years
Male	26	4	0
Female	51	9	3
STEMI	19	2	1
NSTEMI	58	11	3
Mortality	2	5	0

DISCUSSION

In study conducted by Wang WY *et al.* [27], on 582 patients with STEMI 13% of the patients had thyroid abnormalities. 5.84% had low T3 syndrome, 4.81% had subclinical hypothyroidism and 2.41% overt hypothyroidism. TSH and FT4 had no correlation with cardiac biomarkers. Whereas, FT3 level negatively correlated with cardiac biomarkers and lower ejection fraction (EF).

In meta-analysis by Bin Wang *et al.* [28] low T3 syndrome was seen in 16.2% and 41.9% of the patients with acute coronary syndrome and acute myocardial infarction. The low T3 syndrome was associated with increased mortality (HR 1.75, 95% confidence interval).

Kazim SO *et al.* [29] studied 457 patients with STEMI and found thyroid abnormality in 15% of the patients(15). Low T3 syndrome was seen in 30 patients and was associated with poorest outcome. Kenan

Itumur *et al.*, [30] studied patients with cardiac arrest and acute myocardial infarction. The FT3 levels in cardiac arrest group was significantly lower than in the acute myocardial infarction group and control group. After 2 months the FT3 had improved in the cardiac arrest group.

Of the 70 patients studied by Rodrigo CP *et al.*, [31] with acute coronary syndrome, 18.6% had low T3 syndrome and was associated with poor prognosis. There are clear recommendations for screening for hypothyroidism in patients with acute and chronic heart failure [32,33]. There is no mention on the same in patients with acute coronary syndrome.

CONCLUSIONS

The study highlights the fact that low T3 syndrome in patients with acute coronary syndrome (NSTEMI and STEMI) acts as a poor prognosis factor. The study also highlights to the fact that, screening is

less commonly utilised in patients with acute coronary syndrome.

Limitations

The retrospective nature of the study and low sample size are the major limitations of the study. The angiographic severity of the lesions were not available in the study subjects. The changes in the thyroid profile during the follow up period was not available.

The study points to the need of prospective study with good design to evaluate the need of screening patients with acute coronary syndrome with thyroid profile.

ACKNOWLEDGEMENTS

The authors would like to acknowledge the Director of the Institution for his support and encouragement for conducting this study.

DECLARATIONS

Funding: The authors declare that this study did not receive any funding from an external agency
Conflict of interest: None
Ethical approval: Approved by the Institutional Ethics Committee vide letter no. **MIMS/IEC/RP/2017/159 dated. 31.8.2017**

REFERENCES

1. Rajeev Gupta, Indu Mohan, Jagat Narula. Trends in Coronary heart disease epidemiology in India. *Annals of Global Health* 2016; 82 (2):307-315.
2. India RG. Sample Registration System Statistical Report 2005. Report No. 1 of 2006; 2006.
3. World Health Organisation. Global status report on non-communicable diseases 2014. Geneva, Switzerland: World Health Organisation; 2014.
4. Yusuf S, Hawken S, Ōunpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *The lancet*. 2004 Sep 17;364(9438):937-52.
5. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. *Annals of internal medicine*. 2000 Feb 15;132(4):270-8.
6. Harvey CB, Williams GR. Mechanism of thyroid hormone action. *Thyroid* 2002; 12(6): 441-6.
7. Klein I. Thyroid hormone and the cardiovascular system. *Am J Med* 1990; 88: 631-7.
8. Bilezikian JP, Loeb JN. The influence of hyperthyroidism and hypothyroidism on α and β -adrenergic receptor systems and adrenergic responsiveness. *Endocrine Reviews*. 1983 Oct 1;4(4):378-88.
9. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. *Endocr Rev*. 2008;29:76–131.
10. Kim JH, Park JH, Kim SY, Bae HY. The mean platelet volume is positively correlated with serum thyrotropin concentrations in a population of healthy subjects with unsuspected subclinical hypothyroidism. *Thyroid*. 2013;23:31–37.
11. Mayer Jr O, Šimon J, Filipovský J, Plášková M, Pikner R. Hypothyroidism in coronary heart disease and its relation to selected risk factors. *Vascular health and risk management*. 2006 Dec;2(4):499.
12. Rybin V, Steinberg SF. Thyroid hormone represses protein kinase C isoform expression and activity in rat cardiac myocytes. *Circ Res*, 1996; 79: 388–398.
13. Viswanathan G, Balasubramaniam K, Hardy R, Marshall S, Zaman A, Razvi S. Blood Thrombogenicity Is Independently Associated With Serum TSH Levels in Post-Non-ST Elevation Acute Coronary Syndrome. *The Journal of Clinical Endocrinology & Metabolism*. 2014 Mar 14;99(6):E1050-4.
14. Rodondi N, Den Elzen WP, Bauer DC, Cappola AR, Razvi S, Walsh JP, Åsvold BO, Iervasi G, Imaizumi M, Collet TH, Bremner A. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. *Jama*. 2010 Sep 22;304(12):1365-74.
15. Åsvold BO, Bjoro T, Platou C, Vatten LJ. Thyroid function and the risk of coronary heart disease: 12-year follow-up of the hunt study in norway. *Clin Endocrinol (Oxf)*. 2012;77:911–917.
16. Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver JU. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. *The Journal of Clinical Endocrinology & Metabolism*. 2007 May 1;92(5):1715-23.
17. Perk M, O'Neill BJ. The effect of thyroid hormone therapy on angiographic coronary artery disease progression. *Can J Cardiol*. 1997;13:273–276.
18. Caraccio N, Ferrannini E, Monzani F. Lipoprotein profile in subclinical hypothyroidism: Response to levothyroxine replacement, a randomized placebo-controlled study. *J Clin Endocrinol Metab*. 2002;87:1533–1538.
19. Whitesall SE, Mayor GH, Nachreiner RF, Zwemer CF, D'Alecy LG. Acute administration of T3 or rT3 failed to improve outcome following resuscitation from cardiac arrest in dogs. *Resuscitation*. 1996 Nov 1;33(1):53-62.
20. Ojamaa K, Kenessey A, Shenoy R, Klein I. Thyroid hormone metabolism and cardiac gene expression after acute myocardial infarction in the

- rat. Am J Physiol Endocrinol Metab 2000, 279: 1319-1324.
21. Zhang M, Sara JD, Matsuzawa Y, Gharib H, Bell MR, Gulati R, Lerman LO, Lerman A. Clinical outcomes of patients with hypothyroidism undergoing percutaneous coronary intervention. *European heart journal*. 2016 Jan 12;37(26):2055-65.
 22. Arnaldo Moura Neto, Denise Engelbrecht Zantut-Wittmann. Abnormalities of Thyroid hormone metabolism during systemic illness: The low T3 syndrome in different clinical settings. *International Journal of Endocrinology* 2016; Article ID 2157583, 9 pages.
 23. Utiger RD. Decreased extrathyroidal triiodothyronine production in non- thyroidal illness: benefit or harm? *Am J Med* 1980; 69: 807-10.
 24. Yamazaki KA, Yamada EM, Kanaji YO, Shizume KA, Wang DS, Maruo NA, Obara TA, Sato K. Interleukin-6 (IL-6) inhibits thyroid function in the presence of soluble IL-6 receptor in cultured human thyroid follicles. *Endocrinology*. 1996 Nov 1;137(11):4857-63.
 25. Kimura T, Kanda T, Kotajima N, Kuwabara A, Fukumura Y, Kobayashi I. Involvement of circulating interleukin-6 and its receptor in the development of euthyroid sick syndrome in patients with acute myocardial infarction. *European Journal of Endocrinology*. 2000 Aug 1;143(2):179-84.
 26. Yazıcı S, Kırış T, Ceylan US, Terzi S, Erdem A, Atasoy I, Emre A, Yeşilçimen K. Relation of Low T3 to One-Year Mortality in Non-ST-Elevation Acute Coronary Syndrome Patients. *Journal of clinical laboratory analysis*. 2017 Mar 1;31(2).
 27. Wang WY, Tang YD, Yang M, Cui C, Mu M, Qian J, Yang YJ. Free triiodothyronine level indicates the degree of myocardial injury in patients with acute ST-elevation myocardial infarction. *Chinese medical journal*. 2013 Oct;126(20):3926-9.
 28. Wang B, Liu S, Li L, Yao Q, Song R, Shao X, Li Q, Shi X, Zhang JA. Non-thyroidal illness syndrome in patients with cardiovascular diseases: A systematic review and meta-analysis. *International journal of cardiology*. 2017 Jan 1;226:1-0.
 29. Özcan KS, Osmonov D, Toprak E, Güngör B, Tatlısu A, Ekmekçi A, Kaya A, Tayyareci G, Erdinler İ. Sick euthyroid syndrome is associated with poor prognosis in patients with ST segment elevation myocardial infarction undergoing primary percutaneous intervention. *Cardiology journal*. 2014;21(3):238-44.
 30. İltumur K, Olmez G, Arıturk Z, Taskesen T, Toprak N. Clinical investigation: thyroid function test abnormalities in cardiac arrest associated with acute coronary syndrome. *Critical Care*. 2005 Jun 9;9(4):R416.
 31. Pimentel RC, Cardoso GP, Escosteguy CC, Abreu LM. Thyroid hormone profile in acute coronary syndromes. *Arquivos brasileiros de cardiologia*. 2006 Dec;87(6):688-94.
 32. Pearce SH, Brabant G, Duntas LH, Monzani F, Peeters RP, Razvi S, Wemeau JL. 2013 ETA guideline: management of subclinical hypothyroidism. *European thyroid journal*. 2013;2(4):215-28.
 33. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. *European journal of heart failure*. 2012 Aug 1;14(8):803-69.